研究人員>杜鴻運 (Horng Yunn Dou)

杜鴻運照片

感染症與疫苗研究所

連絡電話:(+886) 037-246166 ext.35529 電子郵箱:hydou@nhri.edu.tw

學歷

1989 – 1998 博士, 微生物免疫學研究所, 國立陽明大學
1987 – 1989 碩士, 微生物免疫學研究所, 國防醫學院

經歷

2012/06 – 2006 副研究員, 感染症與疫苗研究所, 國家衛生研究院
2005 – 2012/06 助研究員, 疫苗研發中心, 國家衛生研究院
2005 – 2005 資深研究員, -, 賽德醫藥科技公司
2002 – 2003 訪問學者, 生物技術研究所, 加拿大國家研究委員會
1999 – 2000 訪問學者, 微生物研究所, 美國愛恩斯坦醫學院
1996 – 2005 主任, 檢驗科, 臺北市立慢性病防治醫院
1985 – 1996 醫檢師, 檢驗科, 臺北市仁愛醫院
1981 – 1985 醫檢師, 檢驗科, 省立桃園醫院
1979 – 1981 陸軍少尉, -, 兵役

Honors & Awards

2013 衛生福利部102年防疫績優個人獎
2000 行政院衛生署結核病防治體系重建委員會實驗診斷組專家
1999 – 2000 傅爾布萊特獎學金交換學者獎學金至美國紐約市愛恩斯坦醫學院
1989 微生物免疫學會獎學金
1988 國防醫學院學業績優獎學金
1987 國防醫學院學業績優獎學金

Research Interests

Mycobacterology laboratory research will include TB immuno-pathogenesis, primarily TB genomic study, and recombinant BCG or TB vaccine development. TB research is still needed to provide a solid foundation of understanding of the pathogenesis and development of drug resistance in TB. Subjects including: 1.Surveillance of epidemiology and drug resistance of TB in Taiwan. 2.Understanding the epidemiology that contribute to the development and spread of Drug resistant strains of Mtb 3.Study the host immunity and markers that signal transition from latent to active TB. 4.Understanding the basic biology and immunology of host and pathogen that underlie the development and spread of drug-resistant strains of Mtb. 5.Identification of candidate virulence factor for the pathogenesis of MTB infection and vaccine development

Research Activities & Accomplishment

In general, the public health impact of vaccination programs with new TB vaccines will be dependent crucially on (i) the diversity of circulating Mtb strains, (ii) the mechanisms of competition between strains, and (iii) the strain specificity of these vaccines. In this study, we have revealed the distribution of MTB in Taiwan is closely associated with the ethnicity and migratory population at different historical periods. These results have implications for tuberculosis control efforts, especially for the development of new vaccines. 1.To study the molecular epidemiology of MTB in Taiwan. 2.To fully explore gene variability within the clinical isolate. We will perform the complete genome sequencing and annotation of a clinical isolate of M. tuberculosis strain from different ethnic population, in an attempt to correlate genotypic changes with strain phenotype. 3.To modify BCG by recombinant DNA technology to produce a new live vaccine that expresses immunodominant antigen and/or cytokine with efficacy superior to that of BCG.
NHRI Repository: http://http://ir.nhri.org.tw/handle/3990099045/111
 

Comments are closed.